CONTINEUM THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.12 USD | +0.19% |
|
+5.02% | 0.00% |
Valuation
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 413.9 | - | - |
| Enterprise Value (EV) 1 | 210.2 | 354.1 | 344.4 |
| P/E ratio | - | - | - |
| Yield | - | - | - |
| Capitalization / Revenue | - | 27.6 x | - |
| EV / Revenue | - | 23.6 x | - |
| EV / EBITDA | -4.85 x | -7.6 x | -4.8 x |
| EV / FCF | -5.68 x | -8.43 x | -5.06 x |
| FCF Yield | -17.6% | -11.9% | -19.7% |
| Price to Book | - | -8.74 x | 6.97 x |
| Nbr of stocks (in thousands) | 25,723 | - | - |
| Reference price 2 | 16.09 | 16.09 | 16.09 |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | - | - | 15 | - |
| EBITDA 1 | - | -43.33 | -46.6 | -71.78 |
| EBIT 1 | - | -45.95 | -40.9 | -80.07 |
| Operating Margin | - | - | -272.64% | - |
| Earnings before Tax (EBT) | 23.17 | - | - | - |
| Net income | 22.72 | - | - | - |
| Net margin | - | - | - | - |
| EPS | - | - | - | - |
| Free Cash Flow 1 | - | -37 | -42 | -68 |
| FCF margin | - | - | -280% | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 2/15/24 | - | - | - |
1USD in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | - |
| EBITDA | - | - | - | - |
| EBIT 1 | -9.93 | -9.5 | -12.6 | -15.7 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - |
| Net income | - | - | - | - |
| Net margin | - | - | - | - |
| EPS | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 5/16/24 | - | - | - |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | - | 204 | 59.7 | 69.5 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | - | -37 | -42 | -68 |
| ROE (net income / shareholders' equity) | - | - | - | -663% |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets | - | - | - | - |
| Book Value Per Share 2 | - | - | -1.840 | 2.310 |
| Cash Flow per Share | - | - | - | - |
| Capex 1 | - | 0.43 | 0.35 | 0.55 |
| Capex / Sales | - | - | 2.34% | - |
| Announcement Date | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
16.09
USD
Average target price
28
USD
Spread / Average Target
+74.02%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 414M | |
| +55.55% | 59.34B | |
| +43.17% | 40.24B | |
| -4.71% | 39.88B | |
| -5.56% | 28.55B | |
| +13.76% | 27.26B | |
| -22.00% | 19.23B | |
| +31.50% | 12.61B | |
| +2.16% | 12.49B | |
| +25.70% | 12.28B |
- Stock Market
- Equities
- CTNM Stock
- Financials Contineum Therapeutics, Inc.
